Dutasteride With Tamsulosin HydrochlorideDoubluts
Recommended UrologyAuthority Required (STREAMLINED)Not applicable line
Treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) where treatment has been initiated by a urologist.
1
Submissions
2010–10
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Nov 2010 Recommended Symptoms associated with an enlarged prostate gland
Access path
- TGA registered · Doubluts
TGA label narrower than the PBS population
- Nov 2010Recommended · restricted
vs co-administered dutasteride and prazosin
- PBS listing · Authority Required (STREAMLINED)
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation analysis conducted; no ICER calculated by design
The PBAC recommended the listing of dutasteride with tamsulosin on a cost minimisation basis compared with dutasteride and prazosin. PBAC · 2010
Cost-effectiveness accepted
Decision context
PopulationTreatment of lower urinary tract symptoms due to benign prostatic hyperplasia where treatment has been initiated by a urologist.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2010 | Recommended · restricted | co-administered dutasteride and prazosin | — | RCT · QoL, IPSS, Qmax |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to urologist-initiated treatment; TGA label does not specify prescriber type or treatment initiation requirement.